Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Politicians Want Stronger Role For European Medicines Agency In Health Risk Assessment

The EU ‘Must Learn From The Pandemic Crisis’

Executive Summary

Legislation that will help to build a future “European Health Union” is making its way through the EU legislative process. It includes a greater role for EU health agencies in making preparations for future health emergencies.

You may also be interested in...



EU Launches New Response Body To Tackle Future Health Emergencies

The European Commission has dismissed concerns about the operation of its new emergency response body, saying it will ensure the EU is well prepared for tackling future pandemics and other threats. HERA will complement, not duplicate, work conducted by existing agencies such as the European Medicines Agency, delegates heard at this week’s European Health Forum Gastein virtual conference.

Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination

Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.

EU Parliament Wants Two-Tier Database To Monitor Drug Supplies

High-level negotiations are due to begin later this month on a draft regulation that will give the European Medicines Agency new powers to tackle supply chain issues amid health emergencies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel